D. Azria, M. Ychou, W. Jacot, S. Thezenas, C. Lemanski et al., Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin, Pancreas, vol.25, issue.4, pp.360-365, 2002.
DOI : 10.1097/00006676-200211000-00007

N. Nelson, Pancreatic Cancer Research Matures, JNCI Journal of the National Cancer Institute, vol.99, issue.19, pp.1432-1434, 2007.
DOI : 10.1093/jnci/djm180
URL : http://jnci.oxfordjournals.org/cgi/content/short/99/19/1432

S. Jones, X. Zhang, D. Parsons, J. Lin, R. Leary et al., Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses, Science, vol.321, issue.5897, pp.1801-1806, 2008.
DOI : 10.1126/science.1164368

H. Wong and N. Lemoine, Pancreatic cancer: molecular pathogenesis and new therapeutic targets, Nature Reviews Gastroenterology & Hepatology, vol.3, issue.7, pp.412-422, 2009.
DOI : 10.1038/nrgastro.2009.89

Z. Huang and D. Buchsbaum, Monoclonal antibodies in the treatment of pancreatic cancer, Immunotherapy, vol.1, issue.2, pp.223-239, 2009.
DOI : 10.2217/1750743X.1.2.223

C. Larbouret, B. Robert, I. Navarro-teulon, S. Thèzenas, M. Ladjemi et al., In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas, Clinical Cancer Research, vol.13, issue.11, pp.3356-62, 2007.
DOI : 10.1158/1078-0432.CCR-06-2302
URL : https://hal.archives-ouvertes.fr/inserm-00153693

Y. Yamanaka, H. Friess, M. Kobrin, M. Buchler, H. Beger et al., Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness, Anticancer Res, vol.13, pp.565-569, 1993.

H. Safran, M. Steinhoff, S. Mangray, R. Rathore, T. King et al., Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma, American Journal of Clinical Oncology, vol.24, issue.5, pp.496-499, 2001.
DOI : 10.1097/00000421-200110000-00016

Y. Yarden and M. Sliwkowski, Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-137, 2001.
DOI : 10.1038/35052073

M. Moore, D. Goldstein, J. Hamm, A. Figer, J. Hecht et al., Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, vol.25, issue.15, pp.1960-1966, 2007.
DOI : 10.1200/JCO.2006.07.9525

H. Safran, T. Miner, M. Resnick, T. Dipetrillo, B. Mcnulty et al., Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin, American Journal of Clinical Oncology, vol.31, issue.2, pp.140-144, 2008.
DOI : 10.1097/COC.0b013e318145b9a5

C. Larbouret, B. Robert, C. Bascoul-mollevi, F. Penault-llorca, A. Ho-pun-cheung et al., Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts, Annals of Oncology, vol.21, issue.1, pp.98-103, 2010.
DOI : 10.1093/annonc/mdp496
URL : https://hal.archives-ouvertes.fr/inserm-00431431

C. Germain, C. Larbouret, V. Cesson, A. Donda, W. Held et al., MHC Class I-Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells, Clinical Cancer Research, vol.11, issue.20, pp.7516-7538, 2005.
DOI : 10.1158/1078-0432.CCR-05-0872

N. Gaborit, C. Larbouret, J. Vallaghe, F. Peyrusson, C. Bascoul-mollevi et al., Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers: A NEW METHOD TO EVALUATE THE EFFICIENCY OF TARGETED THERAPY USING MONOCLONAL ANTIBODIES, Journal of Biological Chemistry, vol.286, issue.13, pp.11337-11345, 2011.
DOI : 10.1074/jbc.M111.223503
URL : https://hal.archives-ouvertes.fr/inserm-00576598

C. Vogel, A. Bischof-delaloye, J. Mach, A. Pèlegrin, N. Hardman et al., Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts, British Journal of Cancer, vol.68, issue.4, pp.684-90, 1993.
DOI : 10.1038/bjc.1993.410

R. Clynes, T. Towers, L. Presta, and J. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000.

D. Roopenian and S. Akilesh, FcRn: the neonatal Fc receptor comes of age, Nature Reviews Immunology, vol.100, issue.9, pp.715-740, 2007.
DOI : 10.1038/nri2155

C. Karapetis, S. Khambata-ford, D. Jonker, O. Callaghan, C. Tu et al., Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-1765, 2008.
DOI : 10.1056/NEJMoa0804385

G. Da-cunha-santos, N. Dhani, D. Tu, K. Chin, O. Ludkovski et al., Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer, Cancer, vol.62, issue.suppl 4, pp.5599-5607, 2010.
DOI : 10.1002/cncr.25393

N. Normanno, M. Campiglio, L. De, G. Somenzi, M. Maiello et al., Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth, Annals of Oncology, vol.13, issue.1, pp.65-72, 2002.
DOI : 10.1093/annonc/mdf020

S. Huang, E. Armstrong, S. Benavente, P. Chinnaiyan, and P. Harari, Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor, Cancer Research, vol.64, issue.15, pp.5355-62, 2004.
DOI : 10.1158/0008-5472.CAN-04-0562

M. Karaman, S. Herrgard, D. Treiber, P. Gallant, C. Atteridge et al., A quantitative analysis of kinase inhibitor selectivity, Nature Biotechnology, vol.50, issue.1, pp.127-159, 2008.
DOI : 10.1038/nbt1358

A. Frolov, K. Schuller, C. Tzeng, E. Cannon, B. Ku et al., ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib, Cancer Biology & Therapy, vol.6, issue.4, pp.548-554, 2007.
DOI : 10.4161/cbt.6.4.3849

E. Buck, A. Eyzaguirre, J. Haley, N. Gibson, P. Cagnoni et al., Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity, Molecular Cancer Therapeutics, vol.5, issue.8, pp.2051-2059, 2006.
DOI : 10.1158/1535-7163.MCT-06-0007

M. Komoto, B. Nakata, T. Nishii, H. Kawajiri, O. Shinto et al., evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer, Cancer Science, vol.355, issue.2, pp.468-473, 2010.
DOI : 10.1111/j.1349-7006.2009.01405.x

R. Kimple, A. Vaseva, A. Cox, K. Baerman, B. Calvo et al., Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status, Clinical Cancer Research, vol.16, issue.3, pp.912-923, 2010.
DOI : 10.1158/1078-0432.CCR-09-1324

D. Rusnak, K. Alligood, R. Mullin, G. Spehar, C. Arenas-elliott et al., , GW572016) in an expanded panel of human normal and tumour cell lines, Cell Proliferation, vol.23, issue.2, pp.580-594, 2007.
DOI : 10.1023/A:1006111117877

Z. Wainberg, A. Anghel, A. Desai, R. Ayala, T. Luo et al., Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo, Clinical Cancer Research, vol.16, issue.5, pp.1509-1519, 2010.
DOI : 10.1158/1078-0432.CCR-09-1112

M. Scaltriti, C. Verma, M. Guzman, J. Jimenez, J. Parra et al., Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity, Oncogene, vol.171, issue.6, pp.803-814, 2009.
DOI : 10.1107/S0907444993000423

T. Ben-kasus, B. Schechter, S. Lavi, Y. Yarden, and S. M. , Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis, Proceedings of the National Academy of Sciences, vol.106, issue.9, pp.3294-3299, 2009.
DOI : 10.1073/pnas.0812059106

Z. Ji, F. Mei, J. Xie, and X. Cheng, Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells, Journal of Biological Chemistry, vol.282, issue.19, pp.14048-14055, 2007.
DOI : 10.1074/jbc.M611089200

J. Rinehart, A. Adjei, P. Lorusso, D. Waterhouse, J. Hecht et al., Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer, Journal of Clinical Oncology, vol.22, issue.22, pp.4456-4462, 2004.
DOI : 10.1200/JCO.2004.01.185

A. Jimeno, B. Rubio-viqueira, M. Amador, V. Grunwald, A. Maitra et al., Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer, Molecular Cancer Therapeutics, vol.6, issue.3, pp.1079-1088, 2007.
DOI : 10.1158/1535-7163.MCT-06-0448

D. Meira, V. De-almeida, J. Mororó, I. Nóbrega, L. Bardella et al., Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells, British Journal of Cancer, vol.3, issue.5, pp.782-791, 2009.
DOI : 10.1038/onc.2008.19

R. Ghosh, A. Narasanna, S. Wang, S. Liu, A. Chakrabarty et al., Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers, Cancer Research, vol.71, issue.5, pp.1871-1882, 2011.
DOI : 10.1158/0008-5472.CAN-10-1872

J. Carpentier, M. White, L. Orci, and R. Kahn, Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells, The Journal of Cell Biology, vol.105, issue.6, pp.2751-2762, 1987.
DOI : 10.1083/jcb.105.6.2751

J. Baulida, M. Kraus, M. Alimandi, D. Fiore, P. Carpenter et al., All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired, J Biol Chem, vol.271, pp.5251-5257, 1996.

Z. Wang, L. Zhang, T. Yeung, and C. X. , Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation, Molecular Biology of the Cell, vol.10, issue.5, pp.1621-1636, 1999.
DOI : 10.1091/mbc.10.5.1621